256 related articles for article (PubMed ID: 23900878)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
3. Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
Sidharta PN; van Giersbergen PL; Halabi A; Dingemanse J
Eur J Clin Pharmacol; 2011 Oct; 67(10):977-84. PubMed ID: 21541781
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
[TBL] [Abstract][Full Text] [Related]
6. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Lindegger N; Sidharta PN; Reseski K; Dingemanse J
Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
[TBL] [Abstract][Full Text] [Related]
7. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Raja SG
Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.
Atsmon J; Dingemanse J; Shaikevich D; Volokhov I; Sidharta PN
Clin Pharmacokinet; 2013 Aug; 52(8):685-92. PubMed ID: 23568224
[TBL] [Abstract][Full Text] [Related]
11. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
12. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
[TBL] [Abstract][Full Text] [Related]
13. Macitentan (Opsumit) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
[No Abstract] [Full Text] [Related]
14. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
15. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
17. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
20. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
Raghu G; Million-Rousseau R; Morganti A; Perchenet L; Behr J;
Eur Respir J; 2013 Dec; 42(6):1622-32. PubMed ID: 23682110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
